检索结果-南通市图书馆

Calcium-fortified fresh milk ameliorates postmenopausal osteoporosis via regulation of bone metabolism and gut microbiota in ovariectomized rats

引用

Food Science and Human Wellness 2024年第3期13卷 1258-1270页

作者： Qishan Wang Bin Liu Xianping Li Junying Zhao Zongshen Zhang Weicang Qiao Xinyue Wei Lijun Chen School of Bioengineering Dalian Polytechnic UniversityDalian 116034China National Engineering Research Center of Dairy Health for Maternal and Child Beijing Sanyuan Foods Co.Ltd.Beijing 100163China Beijing Engineering Research Center of Dairy Beijing Sanyuan Foods Co.Ltd.Beijing 100163China

The aging of the global population has made postmenopausal osteoporosis prevention essential;however,pharmacological treatments are ***,we evaluate the effect of calcium-fortified fresh milk(FM)in ameliorating postmenopausal osteoporosis in a rat model established using bilateral *** 3 months of FM(containing vitamin D,and casein phosphopeptides,1000 mg Ca/100 g)or control milk(110 mg Ca/100 g milk)supplementation,bone changes were assessed using dual-energy X-ray absorptiometry,microcomputed tomography,and bone biomechanical *** results revealed that FM can regulate bone metabolism and gut microbiota composition,which act on bone metabolism through pathways associated with steroid hormone biosynthesis,relaxin signaling,serotonergic synapse,and unsaturated fatty acid ***,FM administration significantly increased bone mineral content and density in the lumbar spine and femur,as well as femoral compressive strength,while improving femoral trabecular bone parameters and ***,we found that the effects may be due to increased levels of estrogen,bone formation marker osteocalcin,and procollagen typeⅠN-propeptide,and decreased expression of the bone resorption marker C-telopiptide and tartrate-resistant acid phosphatase ***,the findings suggest that FM is a potential alternative therapeutic option for ameliorating postmenopausal osteoporosis.

关键词： Dairy products Calcium Vitamin D Bone turnover markers Gut microbiota postmenopausal osteoporosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A two-pronged approach to inhibit ferroptosis of MSCs caused by the iron overload in postmenopausal osteoporosis and promote osseointegration of titanium implant

引用

Bioactive Materials 2024年第11期41卷 336-354页

作者： Yulu Yang Xianhui Zhang Yao Yang Pengfei Gao Wuzhe Fan Tao Zheng Weihu Yang Yu Tang Kaiyong Cai Key Laboratory of Biorheological Science and Technology Ministry of Education College of BioengineeringChongqing UniversityChongqing400044China Orthopedics Department The Second Affiliated Hospital of Chongqing Medical UniversityChongqing400010China

postmenopausal osteoporosis(PMOP)is a prevalent condition among elderly *** menopause,women exhibit decreased iron excretion,which is prone to *** design a specific titanium implant for PMOP,we first analyze miRNAs and DNA characteristics of postmenopausal patients with and without *** results indicate that iron overload disrupts iron homeostasis in the pathogenesis of *** experiments confirm that iron overload can cause lipid peroxidation and ferroptosis of MSCs,thus breaking bone *** on the findings above,we have designed a novel Ti implant coated with nanospheres of caffeic acid(CA)and deferoxamine(DFO).CA can bind on the Ti surface through the two adjacent phenolic hydroxyls and polymerize into polycaffeic acid(PCA)dimer,as well as the PCA nanospheres with the repetitive 1,4-benzodioxan *** was grafted with PCA through borate ester *** experimental results showed that modified Ti can inhibit the ferroptosis of MSCs in the pathological environment of PMOP and promote osseointegration in two main ***,DFO was released under high oxidative stress,chelating with excess iron and decreasing the labile iron pool in ***,CA and DFO activated the KEAP1/NRF2/HMOX1 pathway in MSCs and reduced the level of intracellular lipid ***,the ferroptosis of MSCs is inhibited by promoting the SLC7A11/GSH/GPX4 ***,the remained CA coating on the Ti surface could reduce the extracellular oxidative stress and glutathione *** study offers a novel inspiration for the specific design of Ti implants in the treatment of PMOP.

关键词： postmenopausal osteoporosis Iron overload Ferroptosis Caffeic acid nanosphere Ti implant

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Repurpose dasatinib and quercetin:Targeting senescent cells ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration

引用

Bioactive Materials 2023年第7期25卷 13-28页

作者： Ying Wang Lingbin Che Xi Chen Zirui He Dianwen Song Yuan Yuan Changsheng Liu Key Laboratory for Ultrafine Materials of Ministry of Education Frontiers Science Center for Materiobiology and Dynamic ChemistryEngineering Research Center for Biomaterials of Ministry of EducationSchool of Materials Science and EngineeringEast China University of Science and TechnologyShanghai200237PR China Department of Orthopedics Shanghai General HospitalShanghai Jiaotong University School of MedicineShanghai200080China

Clinical therapies developed for estrogen-deficiency-driven postmenopausal osteoporosis(PMO)and related diseases,such as bone degeneration,show multiple adverse effects *** senescent cells(SnCs)and the consequent senescence-associated secretory phenotype(SASP)with a combination of dasatinib and quercetin(DQ)is a recently developed novel therapy for multiple age-related ***,we found that estrogen deficiency induced-bone loss was attributed to a pro-inflammatory microenvironment with SASP secretions and accelerated SnC accumulation,especially senescent mesenchymal stem cells(MSCs)characterized by exhaustion and dysfunction in middle aged *** targeting SnCs with DQ strikingly ameliorated PMO and restored MSC *** administration of DQ and bone morphogenetic protein 2(BMP2)in combination promoted osteogenic differentiation of MSCs and rejuvenated osteoporotic bone *** results repurposed DQ as an attractive therapy for treating PMO and related diseases.

关键词： postmenopausal osteoporosis Dasatinib and quercetin Senescent cells Mesenchymal stem cell Bone regeneration

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

postmenopausal osteoporosis and Osteopenia Management with a Combination of Once-Monthly Oral Ibandronate and Cholecalciferol—A Systematic Review

引用

International Journal of Clinical Medicine 2023年第1期14卷 34-57页

作者： Mauro Geller Mendel Suchmacher Marcio Cohen Spyros G. E. Mezitis Flavia Wajnsztajn-Theil Karin G. Cunha Rafael Nigri Teresópolis Medical Faculty Rio de Janeiro Federal University Rua Bruno Lobo Brazil Carlos Chagas Post-graduation Institute Rio de Janeiro Brazil Orthopedic Surgery and Trauma National Institute Rio de Janeiro Brazil Weill Medical College of Cornell University New York USA Lenox Hill Hospital Northwell Health New York USA Fluminense Federal University Antonio Pedro Hospital Rio de Janeiro Brazil New Jersey Medical School New York USA

postmenopausal osteoporosis and osteopenia are chronic and uncurable conditions that invariably lead to an increased risk of vertebral, hip, and femoral neck fracture if left untreated. Clinical guidelines establish, in general, pharmacological combinations allied to lifestyle changes as the mainstay of their management, and also increasing bone marrow density, lowering fracture risk, and improving quality of life are their main therapeutic goals. The objective of this systematic review was to analyze the available data in the scientific medical literature regarding the role of the ibandronate and cholecalciferol combination in postmenopausal osteoporosis and osteopenia management. Based on our results, we concluded that the above combination is safe and feasible for the clinical control of both conditions.

关键词： Ibandronate Cholecalciferol postmenopausal osteoporosis postmenopausal Osteopenia Systematic Review

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research trends in exercise therapy for the treatment of pain in postmenopausal osteoporosis over the past decade:A bibliometric analysis

引用

World Journal of Orthopedics 2024年第10期15卷 950-964页

作者： Zhao-Qiu Dai Xiao-Yan Gong Rong Zhang Mei-Qin Jin Wei Lu Wen Wen Jie Chen Fang-Jie Lu Yi-Fan Yang Lei Wang Xiao-Jin He Changshu Hospital Affiliated with Nanjing University of Chinese Medicine Changshu 215500Jiangsu ProvinceChina Affiliated Hospital of Nanjing University of Chinese Medicine Jiangsu Province Hospital of Chinese MedicineNanjing 210029Jiangsu ProvinceChina Nanjing University of Chinese Medicine Nanjing 210023Jiangsu ProvinceChina

BACKGROUND postmenopausal osteoporosis(PMOP)is the most common form of primary osteoporosis among women,and the associated pain often drives patients to seek clinical *** studies have highlighted the unique clinical benefits of exercise therapy(ET)in alleviating PMOP-related ***,bibliometric analyses examining collaboration,development trends,and research frontiers in the field of ET for PMOP pain remain *** To explore the research trends in ET for pain treatment in PMOP patients over the past *** All scholarly works were meticulously sourced from the Science Citation Index-Expanded within the prominent Web of Science Core *** the capabilities of CiteSpace 6.2.R5,we conducted a thorough analysis of publications,authors,frequently cited scholars,contributing nations,institutions,journals of significant citation,comprehensive references,and pivotal ***,our examination explored keyword cooccurrences,detailed timelines,and periods of heightened citation *** comprehensive search,from 2014 through 2023,was completed within a single day,on October 11,*** In total,2914 articles were ultimately included in the *** was a rapid increase in annual publication output in 2015,followed by stable growth in subsequent ***,Michael L,is the most prolific author,whereas Ware JE has the most *** United States’global influence is significant,surpassing all other *** University of California System and Harvard University are the most influential academic institutions.J Bone Joint Surg Am is the most influential journal in this field.“Spinal cord injury”is the keyword that has garnered the most attention from *** developmental pattern in this field is characterized by interdisciplinary fusion,with different disciplines converging to drive *** The academic development of the field of ET for pain in PMOP has matured and stabili

关键词： Exercise therapy Pain postmenopausal osteoporosis CiteSpace Bibliometric analysis Web of Science

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and Safety of Risedronate Sodium in Treatment of postmenopausal osteoporosis

引用

Journal of Huazhong University of Science and Technology(Medical Sciences) 2005年第5期25卷 527-529页

作者：李裕明张众志邓秀玲陈璐璐 Department of Endocrinology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Summary： To evaluate the efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis, one-year randomized, double blind clinical trial was performed among 54 women with postmenopausal osteoporosis. The changes were compared in bone mineral density （BMD）, bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium. BMD was measured by dual energy X-ray absorptionmetry （DEXA） and bone turnover marker was detected. The results showed that there was a significant increase in BMD of the lumbar spine （3.29 %±41.18 %, 4.51%±1.64 % respectively） after 6 and 12 months in the risedronate treatment group versus placebo control group （-0.62 %±0.24 %, 0.48 %±0. 18 % respectively）. Bone turnover was decreased to a stable nadir over 6 and 12 months for resorption markers [N-Telopeptide （NTx）, P〈0.05] and over 12 months for formation marker （ALP, P〈0.05; BGP, P〈0. 05）. The safety profile of risedronate sodium was similar to that of placebo. There were no trends toward increased frequency of any adverse experience except for gastrointestinal symptoms （7.1%）, rash （7.1%） and hematuria （3.6 %）, which were usually mild, transient, and resolved with continued treatment. It was concluded that risedronate was an efficacious and safe drug in treatment of postmenopausal osteoporosis.

关键词： risedronate sodium postmenopausal osteoporosis bone mineral density

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Erxian decoction potentially prevents postmenopausal osteoporosis by modulating miR-335: a study based on bioinformatics analysis and preliminary clinical case validation

引用

Traditional Medicine Research 2023年第6期8卷 1-8页

作者： Hao-Qiang Huang Ye Feng Xiao-Feng Shen Yu Zhou Li Qin Feng Xu Qing Wang Department of Orthopaedics Kunshan Hospital of Traditional Chinese MedicineKunshan 215300China School of Stomatology Xuzhou Medical UniversityXuzhou 221000China Department of Orthopedics Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese MedicineSuzhou 215100China Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism School of PharmacyEast China University of Science and TechnologyShanghai 200237China.

Background:miRNAs are closely related to bone *** have shown that Erxian decoction can improve bone metabolism,possibly achieving this regulatory effect through miRNA *** was used to predict the miRNA targets of Erxian decoction for the treatment of postmenopausal osteoporosis,and the results were validated by clinical ***:In this study,we identified possible targets of Erxian decoction in osteoporosis by means of network pharmacological analysis and bioinformatic *** cases of postmenopausal osteoporosis with kidney Yin and Yang deficiency(In traditional Chinese medicine,kidney Yin nourishes and moistens the tissues of the internal organs of the body,while kidney Yang promotes and warms the tissues of the internal organs of the body.)were treated with Erxian decoction for four weeks,and serum bone metabolism indices(P1NP,osteocalcin,andβ-CTX)and miRNA-335-5p expression were measured before and after ***:The constructed miRNA postmenopausal osteoporosis related gene network of the effective compound of the Erxian decoction has 296 points and 981 *** 39 postmenopausal osteoporosis related genes regulated by miRNA-335-5p were enriched in ossification,while the signaling pathways were enriched in rheumatoid arthritis,the Toll signaling pathway,the HIF-1 signaling pathway,and the MAPK signaling *** taking Erxian decoction,the expression of the serum bone formation index(P1NP,osteocalcin)and miRNA-335-5p gene expression levels increased *** alterations in P1NP and osteocalcin were correlated with the changes in ***:Circulating miRNA-335-5p may serve as an important target of Erxian decoction in the treatment of postmenopausal *** effect of Erxian decoction on bone formation is significant,but the underlying mechanism requires further investigation.

关键词： Erxian decoction postmenopausal osteoporosis miRNA-335-5p bone formation bioinformatics clinical cases

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Liuwei Dihuang Pill(六味地黄丸)Treats postmenopausal osteoporosis with Shen(Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression

引用

Chinese Journal of Integrative Medicine 2018年第6期24卷 415-422页

作者： GE Ji-rong XIE Li-hua CHEN Juan LI Sheng-qiang XU Hui-juan LAI Yu-lian QIU Long-long NI Chen-bo Key Research Laboratory of osteoporosis Syndrome Genomics Fujian Academy of Traditional Chinese Medicine Fuzhou 350003 China

Objectives： To investigate the mechanism of Liuwei Dihuang Pill （六味地黄丸, LDP） in treating postmenopausal osteoporosis （PMOP） with Shen （Kidney） yin deficiency. Methods： In this study, 205 cases of PMOP were divided into the PMOP Shen-yin deficiency group （Group A）, PMOP Shen-yang deficiency group （Group B）, PMOP without Shen deficiency group （Group C）, and control group （Group N）. Real-time polymerase chain reaction （RT-PCR） and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin-like cytokine factor 1 （CLCF1）, ankyrin repeat and SOCS box containing 1 （ASB1）, and proldneticin 2 （PROK2） genes and the Janus kinase/signal transducer and activator of transcription （JAK/STAT） signaling pathway. Results： The mRNA （P〈0.05） and protein （P〈0.01） expression levels of the CLCF1 gone in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months, the mRNA expression levels of the CLCF1 gone were obviously up-regulated （P〈0.01）. After 6-month treatment, the expression levels of CLCF1 mRNA and protein were significantly up-regulated （both P〈0.01）, and the average bone density of the top femur had significantly increased （P〈0.05）. In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3. Conclusions： The CLCF1 gone is an important gone associated with PMOP Shen-yin deficiency and the therapeutic effects of LDP may be mediated by up-regulation of CLCF1 gone expression and activation of the JAK/STAT signaling pathway.

关键词： postmenopausal osteoporosis Chinese medicine Shen (Kidney) yin deficiency cardiotrophin- like cytokine factor 1 gone Liuwei Dihuang Pill Janus kinase/signal transducer and activator of transcription signaling pathway

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Network pharmacological study of Zuogui pill and Yougui pill for the treatment of postmenopausal osteoporosis

引用

Aging Communications 2022年第3期4卷 4-13页

作者： Jie Ding Shan-Shan Mei Zhe-Xin Ni Chao-Qin Yu Department of TCM Gynecology School of Traditional Chinese MedicineNaval Medical UniversityShanghai 200433China Institute of Traditional Chinese Medicine Shanghai University of Traditional Chinese MedicineShanghai 200433China

Background:postmenopausal osteoporosis(PMO)is the most common primary osteoporosis in older *** condition imposes a huge economic and medical burden on *** from western medicine,traditional Chinese medicine is also widely used for the treatment of PMO,especially in Asian *** pill(ZGP)and Yougui pill(YGP)are classical formulas for the treatment of PMO with potent clinical *** study aimed to explore the potential active compounds,potential targets,and potential mechanisms of ZGP and YGP for the treatment of ***:Compounds from ZGP and YGP were collected from three online databases,and these compounds were screened by oral bioavailability and *** corresponding targets were determined from the Medicine Systems Pharmacology Database and Analysis *** corresponding targets for PMO were obtained from two disease *** target protein-protein interaction was identified through the STRING platforms and the core targets were ascertained by analyzing the protein-protein interaction network by using Cytoscape ***-related genes were identified via Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses to identify specific biological processes,cellular components,molecular functions and key signalling pathways of ZGP and YGP for PMO ***:A total of 68 compounds were screened from ZGP with 168 putative potential target genes,whereas 99 compounds were screened from YGP with 214 potential target genes associated with *** of the core components included quercetin and kaempferol,and most of the core targets were TP53,AKT1,MAPK1,JUN,TNF,HSP90AA1,APP,IL6,VEGFA,RELA,MAPK8,NR3C1,EGFR,CXCL8,ESR1,FOS and *** Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed that ZGP and YGP treat PMO primarily via regulation of bone formation and resorption,anti-inflammatory immunity and hormonal ***:Our data provided insights i

关键词： Zuogui pill Yougui pill postmenopausal osteoporosis network pharmacological

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A Clinical Study of Yigu Capsule (益骨胶囊) in Treating postmenopausal osteoporosis

引用

Chinese Journal of Integrated Traditional and Western Medicine 2005年第2期11卷 97-103页

作者：张荣华陈可冀陆大祥朱晓峰马晓昌 The First Affiliated Hospital of Jinan University Guangzhou (510632) Xiyuan Hospital China Academy of Traditional Chinese Medicine

Objective: To observe the efficacy and safety of Yigu capsule (益骨胶囊, YGC), a Chinese herbal compound preparation, in treating postmenopausal osteoporosis (PMO) and to explore its possible mechanism. Methods: The clinical study was conducted in a prospective, randomized, double blinded method lasting for 6 months with placebo and positive control. Two hundred and ten PMO patients with confirmed diagnosis were assigned into the YGC group, the calciferol group and the placebo group. Besides being administered element calcium, they were treated with YGC, calciferol capsule and placebo capsule respectively. And such symptoms as newly found fracture and ostealgia, bone mineral density (BMD) of the 2nd-4th lumbar vertebrae (L_ 2-4 ) and upper femur, blood and urinary indexes for bone metabolism, sex hormone level and adverse reaction that occurred in patients were ***: In the YGC group, the total effective rate was 95.50%, with no new occurrence of fractures, which was significantly better than that in the other two groups (P<0.05). Moreover, in the YGC group,the increase rate of BMD was 9.83% in L_ 2-4 , 4.09% in femoral neck, 4.60% in Wards triangle, 3.00% in greater trochanter, which was also better than that in the placebo group (P<0.05, P<0.01). As compared with the placebo group, levels in the YGC group of urinary oxyproline hydroxyproline/creatinine, urinary calcium/creatinine were significantly lower, serum and bone alkaline phosphatase, osteocalcin, estradiol and estradiol/testosterone were significantly higher, but no difference was shown in the comparison of testosterone level. In the observation period, no abnormality in blood or urine routine, liver or renal function was found. Only mild, transient gastro-intestinal response occurred in individual patients, but it did not affect the treatment. Conclusion: YGC could treat PMO effectively, as it could obviously increase the BMD of lumbar vertebrae and coxafemoral bone, elevate the alleviating rate o

关键词： postmenopausal osteoporosis treatment Yigu capsule

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：